| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8fe2a510d519af480caf672dcc67078 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5443
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2019-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a17bbacac4dff312a92b682bdd5979c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2065fc9e01c12575b027b7bf9214c203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_026d0153dfb76d112f07178214edf188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dcc336b31c003f511b03e22c2182898
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e831b85ff03769fafc9995b0049e853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e13433b9c00e971fa9860e1c18bb3a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0d6a4a76dcd5b67b0276e4fc9ca1d92 |
| publicationDate |
2022-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022211815-A1 |
| titleOfInvention |
Combination therapy for the treatment of cancer |
| abstract |
The present disclosure relates to a pharmaceutical composition comprising a STING agonist molecule in combination with an IL-15/IL-15Ra complex. The present combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer. Also provided is the use of such a combination for the manufacture of a medicament; the use of such a combination as a medicine; a kit of parts comprising such a combination; and a method of treatment of such a combination. |
| priorityDate |
2018-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |